Fluoroscopy-guided foam sclerotherapy for varicose veins in the legs: A retrospective cohort analysis with long-term follow-up
Journal of Vascular Surgery: Venous and Lymphatic Disorders · 2023
DOI: 10.1016/j.jvsv.2023.02.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2023. Verfasst von Yongqiang Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, the Forth Affiliated Hospital, Jiangsu University, Zhenjiang, Jiangsu, China. Electronic address: ttjrzyq@163…. Hauptthemen laut MEDLINE: Sclerotherapy, Varicose Veins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVE: To examine the long-term effectiveness of fluoroscopy-guided foam sclerotherapy for varicose veins in the legs. METHODS: This retrospective cohort study included consecutive patients who underwent fluoroscopy-guided foam sclerotherapy for varicose veins in the legs at the authors' center during a period from August 1, 2011, to May 31, 2016. The last follow-up was conducted by a telephone/WeChat interactive interview in May 2022. Recurrence was defined as the presence of varicose veins regardless of symptoms. RESULTS: The final analysis included 94 patients (58.3 ± 7.8 years of age; 43 men; 119 legs). The median Clinical-Etiology-Anatomy-Pathophysiology (CEAP) clinical class was 3.0 (interquartile range [IQR]: 3.0, 4.0). C5 and C6 accounted for 5.0% (6/119) of the legs. The average total amount of the foam sclerosant used during the procedure was 35 ± 12 mL (range: 10-75 mL). No patients developed stroke, deep vein thrombosis, or pulmonary embolism after the treatment. At the last follow-up, the median CEAP clinical class reduction was 3.0. All 119 legs except for class 5 achieved the CEAP clinical class reduction by at least one grade. The median venous clinical severity score was 2.0 (IQR: 1.0, 5.0) at the last follow-up vs 7.0 (IQR: 5.0, 8.0) at the baseline (P < .001). The recurrence rate was 30.9% (29/94) in the overall analysis, 26.6% (25/94) for the great saphenous vein and 4.3% (4/94) for the small saphenous vein (P < .001). Five patients received subsequent surgical treatment, and the remaining patients opted to receive conservative treatments. Among the two C5 legs at the baseline, ulcer recurred in one leg at 3 months after the treatment and healed after conservative treatments. In the four C6 legs at the baseline, ulcer healed within a month in all patients. The rate of hyperpigmentation was 11.8% (14/119). CONCLUSIONS: Long-term outcomes in patients undergoing fluoroscopy-guided foam sclerotherapy are satisfying, with minimal short-term safety concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interventional Radiology, the Forth Affiliated Hospital, Jiangsu University, Zhenjiang, Jiangsu, China. Electronic address: ttjrzyq@163.com.
- Department of Interventional Radiology, the Forth Affiliated Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
Zitieren
APA
Zhu, Y., Wu, D., Song, K., Zhu, H., Li, J., Sun, D., & Lin, J. (2023). Fluoroscopy-guided foam sclerotherapy for varicose veins in the legs: A retrospective cohort analysis with long-term follow-up. Journal of Vascular Surgery: Venous and Lymphatic Disorders. https://doi.org/10.1016/j.jvsv.2023.02.005
Vancouver
Zhu Y, Wu D, Song K, Zhu H, Li J, Sun D, et al. Fluoroscopy-guided foam sclerotherapy for varicose veins in the legs: A retrospective cohort analysis with long-term follow-up. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2023. doi:10.1016/j.jvsv.2023.02.005
BibTeX
@article{Zhu2023,
author = {Zhu, Yongqiang and Wu, Dingquan and Song, Kui and Zhu, Hong and Li, Jie and Sun, Donghui and Lin, Jing},
title = {Fluoroscopy-guided foam sclerotherapy for varicose veins in the legs: A retrospective cohort analysis with long-term follow-up},
journal = {Journal of Vascular Surgery: Venous and Lymphatic Disorders},
year = {2023},
doi = {10.1016/j.jvsv.2023.02.005}
}
EUVIMED